Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05363280
PHASE2

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

Sponsor: Advenchen Pharmaceuticals, LLC.

View on ClinicalTrials.gov

Summary

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .

Official title: A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in ≥2nd Line Small Cell Lung Cancer (SCLC) Treatment

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2022-11-01

Completion Date

2026-12

Last Updated

2025-09-23

Healthy Volunteers

No

Interventions

DRUG

AL8326 low dose group

Taken AL3826 at low dose orally

DRUG

AL8326 middle dose group

Taken AL3826 at middle dose orally

DRUG

AL8326 high dose group

Taken AL3826 at high dose orally

Locations (6)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Northwestern University

Chicago, Illinois, United States

Siteman Cancer Center, Washington University

St Louis, Missouri, United States

Cleveland Clinic

Cleveland, Ohio, United States

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Universitario Ramón Y Cajal

Madrid, Spain